Basic Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2017; 23(15): 2716-2722
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2716
Role of Δ133p53 isoform in NF-κB inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells
Hong-Mei Zhang, Xiao-Guang Sang, Yan-Ze Wang, Can Cui, Li Zhang, Wan-Sheng Ji
Hong-Mei Zhang, Li Zhang, Wan-Sheng Ji, Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China
Xiao-Guang Sang, Department of Gastroenterology, Shouguang People’s Hospital, Weifang 262700, Shandong Province, China
Yan-Ze Wang, Can Cui, Graduate School of Weifang Medical University, Weifang 261042, Shandong Province, China
Author contributions: Zhang HM and Ji WS designed experiments; Zhang HM and Sang XG contributed most reagents; Sang XG, Wang YZ, Cui C and Zhang L performed research; Wang YZ, Cui C and Zhang L analyzed data; and Zhang HM and Ji WS wrote the paper.
Supported by Shandong Provincial Award Foundation for Youth and Middle-aged Scientist, No. BS2010SW034.
Institutional review board statement: The study design and conduct conformed to the Declaration of Helsinki, and was approved by the Ethics Committee of the Affiliated Hospital of Weifang Medical University.
Conflict-of-interest statement: All of the authors declare that they have no competing interests regarding this paper.
Data sharing statement: The data and materials can be obtained on request from the authors.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Wan-Sheng Ji, Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China. wanshengji68@126.com
Telephone: +86-536-3081251 Fax: +86-536-8650309
Received: December 2, 2016
Peer-review started: December 6, 2016
First decision: January 19, 2017
Revised: February 14, 2017
Accepted: March 15, 2017
Article in press: March 15, 2017
Published online: April 21, 2017
Core Tip

Core tip: Intestinal-type of gastric cancer develops from chronic gastritis. Δ133p53 isoform has been recently identified as an oncogenic actor that is pivotal in Helicobacter pylori-driven progression of chronic gastritis to gastric cancerogenesis. These results suggest that Δ133p53 isoform is required in pyrrolidine dithiocarbamate-induced inhibition of MKN45 gastric cancer cells, and disturbance in the cross-talk between p53 and nuclear factor-κB pathways is a promising target in pharmaceutical research for the development of treatment strategies against intestinal-type gastric cancer.